Thursday – Basic Science Track 1B Survey

Name Badge ID(Required)

Full Name(Required)

Enter your first and last names as you would like them to appear on your certificates.

First Last

Email(Required)

Enter the email you used to register for TOXINS 2022.

Please evaluate the speakers

Overall Evaluation

Topic and Speaker(s)

	Excellent	Good	Fair	Poor
Cryo-EM structures of the 300 kDa progenitor toxin complexes of BoNT/B, BoNT/X, BoNT/Wo and PMP1 Pål Stenmark, PhD (Sweden)
Receptor-binding mechanism of botulinum neurotoxins Rongsheng Jin, PhD (USA)
Lessons learnt from the structural aspects of botulinum neurotoxin research so far K. Ravi Acharya, PhD (UK)
Excitation-contraction-coupling inhibitors potentiate the activity of botulinum neurotoxin type A at the neuromuscular junction Mickaël Machicoane, PhD (Switzerland)
Structure-based design of a botulinum neurotoxin with triple receptor recognition Geoffrey Masuyer, PhD (Sweden)

Presentation free of commercial bias?

	Yes	No
Cryo-EM structures of the 300 kDa progenitor toxin complexes of BoNT/B, BoNT/X, BoNT/Wo and PMP1 Pål Stenmark, PhD (Sweden)
Receptor-binding mechanism of botulinum neurotoxins Rongsheng Jin, PhD (USA)
Lessons learnt from the structural aspects of botulinum neurotoxin research so far K. Ravi Acharya, PhD (UK)
Excitation-contraction-coupling inhibitors potentiate the activity of botulinum neurotoxin type A at the neuromuscular junction Mickaël Machicoane, PhD (Switzerland)
Structure-based design of a botulinum neurotoxin with triple receptor recognition Geoffrey Masuyer, PhD (Sweden)

If you answered “No, this presentation was not free of commercial bias”, on any of the above, please explain your reason(s).

Applicable to my practice/research

	Yes	No
Cryo-EM structures of the 300 kDa progenitor toxin complexes of BoNT/B, BoNT/X, BoNT/Wo and PMP1 Pål Stenmark, PhD (Sweden)
Receptor-binding mechanism of botulinum neurotoxins Rongsheng Jin, PhD (USA)
Lessons learnt from the structural aspects of botulinum neurotoxin research so far K. Ravi Acharya, PhD (UK)
Excitation-contraction-coupling inhibitors potentiate the activity of botulinum neurotoxin type A at the neuromuscular junction Mickaël Machicoane, PhD (Switzerland)
Structure-based design of a botulinum neurotoxin with triple receptor recognition Geoffrey Masuyer, PhD (Sweden)

This activity should improve my

	Strongly disagree	Disagree	Neutral	Agree	Strongly agree
Ability to evaluate the latest clinical and scientific research into botulinum neurotoxins
Understanding of the clinical utility of botulinum neurotoxins
Understanding of potential new therapeutic applications of botulinum neurotoxins
Biomedical knowledge of botulinum and other neurotoxins and their application in enhancing therapeutics and improving care

Comments